Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors - Concepedia

Concepedia

Publication | Open Access

Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors

DOI Full Paper Access

17

Citations

30

References

2024

Year

Diwakar Davar, Benedito A. Carneiro, Grace K. Dy, Siddharth Sheth, Mitesh J. Borad, Kevin J. Harrington, Sandip Pravin Patel, Evanthia Galanis, Adel Samson, Sonia Agrawal,

Journal for ImmunoTherapy of Cancer

Abstract

NCT03889275.

References

	Year	Citations

Page 1